Benjamin Ebert became CEO of Dana-Farber Cancer Institute at a turning point in late 2024, leading the organization in the midst of building a massive $1.6 billion cancer hospital and ending its partnership with Brigham and Women’s Hospital and partnering instead with Beth Israel Lahey Health.
The wheels of change were set in motion by his predecessor, Laurie Glimcher, who led Dana-Farber from 2016 to 2024. But Evert, a medical oncologist who previously served as chief of medical oncology at the institute for seven years, has no shortage of ideas and visions for Dana-Farber’s future. He recently detailed this to the Globe. This conversation has been edited for length and clarity.
You have started this huge project that your predecessor started. Things are going well, but it seems like there’s still a lot of work to be done.
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article and get in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
